読み込み中
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
前日終値
$7.46
−$0.11 · -1.45%
日中の時刻はETです。市場データは遅延する場合があります。
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
日中レンジ
現在 $7.46
52週レンジ
現在 $7.46
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
40
割高
センチメント
59
まちまち
リスク
58
やや高いリスク
モメンタム
39
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
日中レンジ
現在 $7.46
52週レンジ
現在 $7.46
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 2133.17万 USD | 1607.93万 USD | 1533.19万 USD | 1362.99万 USD | 1017.22万 USD |
| 販売・一般管理 | 1710.24万 USD | 1092.41万 USD | 563.5万 USD | 398.76万 USD | 820.35万 USD |
| 営業費用 | 3843.4万 USD | 2700.34万 USD | 2096.69万 USD | 1761.75万 USD | 1837.57万 USD |
| 受取利息 | 141.25万 USD | 115.99万 USD | 64.98万 USD | 43.18万 USD | — |
| 支払利息 | — | 60.36万 USD | 88.11万 USD | 98.29万 USD | 116.49万 USD |
| 減価償却費と償却費 | 23.77万 USD | 17.17万 USD | 11.71万 USD | 14.79万 USD | 8.75万 USD |
| 営業利益 | −3843.4万 USD | −2700.34万 USD | −2096.69万 USD | −1761.75万 USD | −1837.57万 USD |
| 純利益 | −3857.61万 USD | −2550.25万 USD | −2124.82万 USD | −1848.96万 USD | −2395.79万 USD |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$17.50
上昇余地（134.58%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
